{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:11:37Z","timestamp":1789837897380,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006388","name":"H\u00f4pitaux Universitaires de Gen\u00e8ve","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000185","name":"Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cmi.2026.01.019","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:09:30Z","timestamp":1769533770000},"page":"1158-1164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSV\u0394G-ZEBOV-GP-primed volunteers (Boost-EBOV)"],"prefix":"10.1016","volume":"32","author":[{"given":"Angela","family":"Huttner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"de La Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Boehm-Bosmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fontannaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lemeille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Edith","family":"Nepveu-Traversy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventure","family":"Orizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Reuschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Sharkhith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Pignac-Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Liebowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud M.","family":"Didierlaurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire-Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.01.019_bib1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.019_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14760584.2018.1546582","article-title":"Durability of single-dose rVSV-ZEBOV vaccine responses: What do we know?","volume":"17","author":"Huttner","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2026.01.019_bib4","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.cmi.2023.08.026","article-title":"Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability","volume":"29","author":"Huttner","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.019_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable Vesicular Stomatitis Virus (VSV)-Specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans","volume":"219","author":"Poetsch","year":"2019","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2026.01.019_bib6","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1093\/infdis\/jiv175","article-title":"Optimization of prime-boost vaccination strategies against mouse-adapted Ebolavirus in a short-term protection study","volume":"212","author":"Aviles","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.019_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon(R) ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.019_bib8","doi-asserted-by":"crossref","first-page":"taab086","DOI":"10.1093\/jtm\/taab086","article-title":"Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: An observational study","volume":"28","author":"Carnino","year":"2021","journal-title":"J Travel Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: An observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.019_bib10","series-title":"Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","year":"2007"},{"key":"10.1016\/j.cmi.2026.01.019_bib11","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized trial of vaccines for Zaire Ebola virus disease","volume":"387","author":"Team","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib12","doi-asserted-by":"crossref","first-page":"104562","DOI":"10.1016\/j.ebiom.2023.104562","article-title":"Immune response of a two-dose heterologous Ebola vaccine regimen: Summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory","volume":"91","author":"McLean","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2026.01.019_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.019_bib14","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2026.01.019_bib15","doi-asserted-by":"crossref","first-page":"1156758","DOI":"10.3389\/fimmu.2023.1156758","article-title":"Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection","volume":"14","author":"Escudero-Perez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.01.019_bib16","doi-asserted-by":"crossref","first-page":"158ra46","DOI":"10.1126\/scitranslmed.3004582","article-title":"Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates","volume":"4","author":"Wong","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/infdis\/jiy537","article-title":"Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines","volume":"219","author":"Patel","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.019_bib19","doi-asserted-by":"crossref","first-page":"155ra38","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib20","doi-asserted-by":"crossref","first-page":"16025","DOI":"10.1038\/mto.2016.25","article-title":"Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100","volume":"3","author":"Morrow","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.cmi.2026.01.019_bib21","doi-asserted-by":"crossref","first-page":"21742","DOI":"10.1038\/s41598-024-67797-x","article-title":"COMPARING vaccine manufacturing technologies recombinant DNA vs in vitro transcribed (IVT) mRNA","volume":"14","author":"Davidopoulou","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2026.01.019_bib22","series-title":"Disease Outbreak News (DONs)","year":"2025"},{"key":"10.1016\/j.cmi.2026.01.019_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/v13030382","article-title":"Multivalent DNA vaccines as a strategy to combat multiple concurrent epidemics: Mosquito-borne and hemorrhagic fever viruses","volume":"13","author":"Jiang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2026.01.019_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2026.01.019_bib25","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2026.01.019_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.01.019_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00163-0","article-title":"Safety and immunogenicity of a delayed booster dose of the rVSVDeltaG-ZEBOV-GP vaccine for prevention of Ebola virus disease: A multicentre, open-label, phase 2 randomised controlled trial","volume":"5","author":"Davey","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2026.01.019_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:33:44Z","timestamp":1781530424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1198743X26000248"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSV\u0394G-ZEBOV-GP-primed volunteers (Boost-EBOV)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.039","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}